BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 23879057)

  • 1. [Endothelial dysfunction in rheumatic patients].
    Shilkina NP; Butusova SV
    Klin Med (Mosk); 2013; 91(4):58-61. PubMed ID: 23879057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Markers of endothelial activation in rheumatoid arthritis].
    Shilikina NP; Yunonin IE; Vinogradov AA; Butusova SV
    Ter Arkh; 2012; 84(8):29-32. PubMed ID: 22994085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating endothelial cells, endothelial apoptosis and soluble markers of endothelial dysfunction in patients with systemic lupus erythematosus-related vasculitis.
    Kluz J; Kopeć W; Jakobsche-Policht U; Adamiec R
    Int Angiol; 2009 Jun; 28(3):192-201. PubMed ID: 19506538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [System of microcirculation, markers of vascular wall damage and systematicity of the process in rheumatic diseases].
    Shilkina NP; Butusova SV; Driazhenkova IV
    Angiol Sosud Khir; 2014; 20(1):27-34. PubMed ID: 24722018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Markers of vascular endothelium activation in gout].
    Lapkina NA; Baranov AA; Barskova VG; Abaĭtova NE; Iakunina IA
    Ter Arkh; 2005; 77(5):62-5. PubMed ID: 15989007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pentraxin 3 as a biomarker of local inflammatory response to vascular injury in systemic lupus erythematosus.
    Cieślik P; Hrycek A
    Autoimmunity; 2015 Jun; 48(4):242-50. PubMed ID: 25401491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does reduction of disease activity improve early markers of cardiovascular disease in newly diagnosed rheumatoid arthritis patients?
    de Groot L; Jager NA; Westra J; Smit AJ; Kallenberg CG; Posthumus MD; Bijl M
    Rheumatology (Oxford); 2015 Jul; 54(7):1257-61. PubMed ID: 25587178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission.
    Wais T; Fierz W; Stoll T; Villiger PM
    J Rheumatol; 2003 Oct; 30(10):2133-9. PubMed ID: 14528506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent increase in plasma thrombomodulin in patients with a history of lupus nephritis: endothelial cell activation markers.
    Frijns R; Fijnheer R; Schiel A; Donders R; Sixma J; Derksen R
    J Rheumatol; 2001 Mar; 28(3):514-9. PubMed ID: 11296951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble adhesion molecules in pediatric rheumatic diseases.
    Bloom BJ; Miller LC; Blier PR
    J Rheumatol; 2002 Apr; 29(4):832-6. PubMed ID: 11950029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Markers of endothelial dysfunction (VCAM-1 and vWF) in chronic hepatitis C].
    Antonova TV; Romanova MA; Lymar' IuV
    Ter Arkh; 2013; 85(12):86-9. PubMed ID: 24640675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of nailfold capillaroscopy in systemic lupus erythematosus: correlation with endothelial cell activation markers and disease activity.
    Kuryliszyn-Moskal A; Ciolkiewicz M; Klimiuk PA; Sierakowski S
    Scand J Rheumatol; 2009; 38(1):38-45. PubMed ID: 18991188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers of endothelial dysfunction in patients with primary focal segmental glomerulosclerosis.
    Zhang Q; Zeng C; Fu Y; Cheng Z; Zhang J; Liu Z
    Nephrology (Carlton); 2012 May; 17(4):338-45. PubMed ID: 22295953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor in patients with rheumatoid arthritis.
    Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
    Scand J Rheumatol; 2009; 38(6):439-44. PubMed ID: 19922018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelial cell activation in cutaneous vasculitis.
    Jurd KM; Stephens CJ; Black MM; Hunt BJ
    Clin Exp Dermatol; 1996 Jan; 21(1):28-32. PubMed ID: 8689765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Endothelial damage and circadian blood pressure profile in rheumatoid arthritis].
    Shilkina NP; Yunonin IE; Butusova SV; Mikhailova EV; Vinogradov AA
    Ter Arkh; 2019 May; 91(5):89-95. PubMed ID: 32598682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating endothelial cells and rheumatoid arthritis: relationship with plasma markers of endothelial damage/dysfunction.
    Foster W; Shantsila E; Carruthers D; Lip GY; Blann AD
    Rheumatology (Oxford); 2009 Mar; 48(3):285-8. PubMed ID: 19153145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-endothelial cell autoantibodies and soluble markers of endothelial cell dysfunction in systemic lupus erythematosus.
    Constans J; Dupuy R; Blann AD; Resplandy F; Seigneur M; Renard M; Longy-Boursier M; Schaeverbeke T; Guérin V; Boisseau MR; Conri C
    J Rheumatol; 2003 Sep; 30(9):1963-6. PubMed ID: 12966599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced glycation end-products inhibition improves endothelial dysfunction in rheumatoid arthritis.
    Syngle A; Vohra K; Garg N; Kaur L; Chand P
    Int J Rheum Dis; 2012 Feb; 15(1):45-55. PubMed ID: 22324946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating proangiogenic molecules PIGF, SDF-1 and sVCAM-1 in patients with systemic lupus erythematosus.
    Robak E; Kulczycka L; Sysa-Jedrzejowska A; Wierzbowska A; Robak T
    Eur Cytokine Netw; 2007 Dec; 18(4):181-7. PubMed ID: 17964973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.